The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Early switching to pembrolizumab (Pe) during first-line platinum-based chemotherapy (PCT) in patients (pts) with metastatic urothelial carcinoma (mUC).
 
Yuki Endo
Stock and Other Ownership Interests - Chugai Pharma; Daiichi Sankyo
 
Go Kimura
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Ono Yakuhin
Consulting or Advisory Role - Eisai
Speakers' Bureau - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Janssen; Merck; MSD; Ono Yakuhin; Sanofi; Takeda
 
Jun Akatsuka
No Relationships to Disclose
 
Hayato Takeda
No Relationships to Disclose
 
Masato Yanagi
No Relationships to Disclose
 
Hikaru Mikami
No Relationships to Disclose
 
Hiroya Hasegawa
No Relationships to Disclose
 
Mami Taniuchi
No Relationships to Disclose
 
Akifumi Katsu
No Relationships to Disclose
 
Ryota Funato
No Relationships to Disclose
 
Yuka Toyama
No Relationships to Disclose
 
Yukihiro Kondo
No Relationships to Disclose